# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Bristol Myers Squibb (NYSE:BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progressi...
Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming ph...